Icepharma A/S

A/SActiveAdvertising protection

CVR 36393459Høje Taastrup Boulevard 53, 2630 TaastrupWholesale of pharmaceutical and medical goods· NACE 4646Est. 2014 · 11 years old1 employeeshttps://www.icepharma.dk

Overview

Icepharma A/S is a Danish A/S based in Taastrup, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2014, the company has 1 employee and reported a gross profit of DKK 1.0m in its latest annual filing.

Gross profit 2025

1M DKK

−344% vs 2024

EBITDA margin (of gross profit)

−228.6 %

+36% vs 2024

Net profit 2025

1.9M DKK

+153% vs 2024

Key ratios

See full ratios →

88.5 %

Very strong

Among the 20% highest rated companies in the industry

20212025

8.7×

Very strong

Among the 10% highest rated companies in the industry

20212025

16.2 %

Very strong

Among the 20% highest rated companies in the industry

20212025

EBITDA — year on year

DKK thousands

Key figures

Annual report 2025

Gross profit	1M DKK	-344%
EBITDA	-2.3M DKK	+36%
Net profit	1.9M DKK	+153%
Total assets	11.6M DKK	+129%
Equity	10.3M DKK	+175%
Employees	1	—

Contact

Address

Høje Taastrup Boulevard 53, 2630 Taastrup

Phone

+45 2215 0409

info@icepharma.dk

Website

https://www.icepharma.dk

Advertising protection

Active — opted out of marketing use

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2025), Icepharma A/S reported a gross profit of DKK 1.0m. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 1.9m, and the EBITDA margin stood at -228.6%.

At the end of 2025, equity financed 88.5% of the balance sheet, and current assets covered short-term debt 8.7 times.

Financials

Gross profit

DKK thousands

EBITDA

DKK thousands

Income statement

DKK thousands

Item	2025	2024	2023	2022	2021
Gross profit	1,000	-410	-2,176	-1,026	-2,436
Staff expenses	-3,287	-3,152	-3,267	-3,685	-2,994
EBITDA	-2,287	-3,562	-5,443	-4,711	-5,430
Depreciation & amort.	-0	-0	-0	-0	-0
EBIT	-2,287	-3,562	-5,443	-4,711	-5,430
Net financials	-10	-1	-12	-37	6
Profit before tax	-2,296	-3,563	-5,455	-4,748	-5,424
Tax	-4,180	-0	-27	-0	-0
Net profit	1,884	-3,563	-5,428	-4,748	-5,424

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2025	2024	2023	2022	2021
Total assets	11,644	5,077	4,714	3,502	2,916
Equity	10,305	3,745	2,231	1,648	690
Long-term debt	0	0	313	303	293
Short-term debt	1,339	1,332	2,171	1,550	1,933
Total debt	1,339	1,332	2,484	1,854	2,226

Financial ratios

5-year trend

EBITDA margin (of gross profit)

-228.6 %

20212025

Equity ratio

88.5 %

Very strong

Among the 20% highest rated companies in the industry

20212025

Return on equity

18.3 %

Average

Around the average of companies in the same industry

20212025

Net profit margin (of gross profit)

188.4 %

20212025

Asset turnover (of gross profit)

0.09×

20212025

Debt / equity

0.13×

Very strong

Among the 20% highest rated companies in the industry

20212025

Sector performance

23 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on equity (ROE)Average

Around the average of companies in the same industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Very strong

Among the 20% highest rated companies in the industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Strong

Among the 40% highest rated companies in the industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Very weak

Among the 20% lowest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioVery weak

Among the 20% lowest rated companies in the industry

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Liquidity

Current ratioVery strong

Among the 10% highest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioVery strong

Among the 20% highest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioStrong

Among the 40% highest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityStrong

Among the 30% highest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalVery strong

Among the 10% highest rated companies in the industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioVery weak

Among the 10% lowest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioVery strong

Among the 20% highest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioVery strong

Among the 10% highest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityVery strong

Among the 20% highest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityVery strong

Among the 20% highest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtVery strong

Among the 10% highest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtVery weak

Among the 10% lowest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageVery weak

Among the 10% lowest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtStrong

Among the 40% highest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginVery strong

Among the 20% highest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Equity to contributed capitalStrong

Among the 30% highest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityVery strong

Among the 10% highest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtAverage

Around the average of companies in the same industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since
Current (1)
HÞ Hörður Þórhallsson Management	Management	2016

Former (1)


PP Peter Popowicz Management	Management	2014 – 2016

Board of directors

Non-executive oversight

Name	Role	Member since
Current (3)
JI Jóhann Ingi Kristjánsson Board of Directors	Board of Directors	2017
KJ Kristján Johannsson Chairman	Chairman	2014
PI Petrea Ingileif Gudmundsdottir Board of Directors	Board of Directors	2017

Former (2)


MG Margrét Guðmundsdóttir Board of Directors	Board of Directors	2014 – 2017
BH Bessi Húnfjörð Jóhannesson Board of Directors	Board of Directors	2014 – 2017

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
Eignarhaldsfélagið Lyng ehf	Individual	100%	100%	2014

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

No registered parent or subsidiaries

Board network connections

Board members of Icepharma A/S hold no positions in other companies.

Frequently asked questions

What is the CVR number of Icepharma A/S?

Icepharma A/S is registered with CVR / Virk under CVR 36393459.

What is the gross profit of Icepharma A/S?

Icepharma A/S reported a gross profit of DKK 1.0m in 2025.

How many employees does Icepharma A/S have?

Icepharma A/S employs 1 people as of the latest annual report.

Who is the chairman of Icepharma A/S?

Kristján Johannsson chairs the board of Icepharma A/S.

Where is Icepharma A/S headquartered?

Icepharma A/S's registered address is Høje Taastrup Boulevard 53.